Sinobiomed's subsidiary, Shanghai Wanxing Bio-pharmaceuticals, has received a patent grant notice from the State Intellectual Property Office of the People's Republic of China (PRC) for its purified recombinant batroxobin with high bioactivity.
The patent application (031160549) comprises a DNA recombinant technology to fabricate batroxobin, which exists naturally in the venom of the pallas pit viper. The invention also covers the synthesis of the batroxobin gene, as well as the expression, purification and characterization of batroxobin. Shanghai Wanxing applied for the Chinese patent for rBAT in 2003. In addition, The Patent Cooperation Treaty (PCT) issued Sinobiomed's recombinant batroxobin international application number PCT/CN2007/001036 on March 30, 2007.
Natural batroxobin is the world's most prescribed biological anti-bleeding agent, but also has high production costs and safety concerns. In China, natural batroxobin currently has more than 80 percent of the domestic market.
rBAT is said to be the world's first batroxobin synthesized through gene recombination. Shanghai Wanxing's low-cost, high-yield production process enhances bioactivity and guarantees the highest levels of purity. Shanghai Wanxing developed rBAT to prevent and treat surgical bleeding; it is now in phase II clinical trials.